Dr. Vogelzang Discusses Cabozantinib Trial Design

Nicholas J. Vogelzang, MD
Published: Thursday, Jun 09, 2011

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada discusses cabozantinib trial design.

Dr. Vogelzang says the cabozantinib trial was a nine arm trial. Some of the arms included breast, ovarian, prostate, hepatocellular, lung, gastrointestinal and small cell lung cancer. The trial included nine different categories of patients. All patients received twelve weeks of treatment, after which they underwent scans and appropriate blood tests. If at twelve weeks they were benefiting (as measured by a variety of factors), they were allowed to stay on the drug. If they were felt to be stable, they were randomized to either continue the drug or discontinue the drug. If their X-rays at any time had shown that the cancer was growing, the patient would come off study.
Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada discusses cabozantinib trial design.

Dr. Vogelzang says the cabozantinib trial was a nine arm trial. Some of the arms included breast, ovarian, prostate, hepatocellular, lung, gastrointestinal and small cell lung cancer. The trial included nine different categories of patients. All patients received twelve weeks of treatment, after which they underwent scans and appropriate blood tests. If at twelve weeks they were benefiting (as measured by a variety of factors), they were allowed to stay on the drug. If they were felt to be stable, they were randomized to either continue the drug or discontinue the drug. If their X-rays at any time had shown that the cancer was growing, the patient would come off study.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x